Date: 2014-05-27
Type of information: Product acquisition
Compound: ADC-1013
Company: BioInvent (Sweden) Alligator Bioscience (Sweden)
Therapeutic area: Cancer - Oncology
Type agreement: product acquisition
Action mechanism:
- monoclonal antibody. ADC-1013 is an agonistic monoclonal antibody targeting the human CD40 receptor on dendritic cells. This antibody has been FIND®-optimized for optimal properties for local immunotherapy. These properties include high affinity and potency, as well as functionality in the tumor microenvironment. The anti-tumor effects of ADC-1013 were first assessed in a bladder cancer model.
Disease:
Details:
- • On May 27, 2014, BioInvent International announced that the company has sold back all its rights to drug development candidate ADC-1013 to former partner Alligator Bioscience for an undisclosed sum. BioInvent has successfully manufactured ADC-1013 (a FIND® optimized n-CoDeR® antibody) and will fulfill the remaining CMC activities required to supply drug product to the First-in-Human study, expected to commence by the end of 2014. BioInvent will continue to focus its efforts on its fully owned drug development candidates BI-505 in phase II for Multiple Myeloma and BI-1206, where a First-in-Human study in non-Hodgkin’s Lymphoma is expected to start late 2014/early 2015.
Financial terms:
Latest news:
Is general: Yes
